Xiao Di, Zhang Si-Min, Li Xi, Yin Ji-Ye, Gong Wei-Jing, Zheng Yi, Xu Xiao-Jing, Lin Xu, Ji Li-Nong, Liu Rang-Ru, Tang Qiang, Zhang Wei, Zhou Hong-Hao, Han Xue-Yao, Liu Zhao-Qian
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.
Pharmacogenomics. 2015;16(14):1621-9. doi: 10.2217/pgs.15.95. Epub 2015 Sep 24.
To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients.
PATIENTS & METHODS: 768 SNPs in or close to 207 genes were genotyped in 84 patients treated with metformin + glibenclamide/Xiaoke Pill. Significant SNPs were then verified in 107 recent-onset overweight or obese T2DM patients treated with metformin alone. Genotyping was done by Illumina GoldenGate Assay.
In the discovery stage, 22 SNPs were nominally significant. IL1B rs1143623 (p = 0.011) and EEF1A1P11-RPL7P9 rs10783050 (p = 0.021) were still significantly associated with the relative change of HbA1c in the replication stage.
IL1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms may contribute to metformin's glucose-lowing efficacy in overweight or obese Chinese T2DM patients.
研究超重或肥胖的中国2型糖尿病（T2DM）患者中潜在的基因对二甲双胍疗效的影响。
对84例接受二甲双胍+格列本脲/消渴丸治疗的患者进行了207个基因内部或附近的768个单核苷酸多态性（SNP）的基因分型。然后在107例近期发病的仅接受二甲双胍治疗的超重或肥胖T2DM患者中对显著的SNP进行验证。基因分型通过Illumina GoldenGate检测法进行。
在发现阶段，22个SNP具有名义上的显著性。白细胞介素1β（IL1B）基因的rs1143623（p = 0.011）和EEF1A1P11-RPL7P9基因的rs10783050（p = 0.021）在验证阶段仍与糖化血红蛋白（HbA1c）的相对变化显著相关。
IL1B基因的rs1143623和EEF1A1P11-RPL7P9基因的rs10783050多态性可能有助于二甲双胍对超重或肥胖的中国T2DM患者的降糖疗效。
